NIO Inc. Sponsored ADR Class A (NIO.US) Q4 revenue guidance ranks first among new forces, JPMorgan sees good profit prospects and rates it as "overweight".
J.P. Morgan expressed a clear positive outlook on NIO's profit prospects in its latest research report.
In the latest research report released by J.P. Morgan, a strong bullish view on the profit prospects of NIO Inc. Sponsored ADR Class A (NIO.US) was expressed. The institution pointed out that NIO Inc. Sponsored ADR Class A is expected to achieve profitability in the fourth quarter of this year, mainly driven by the delivery of high-priced new car models, continued cost control, and operational efficiency optimization. The core judgment is that, with the continuous release of new car models, strict cost control, and improved operational capabilities, the company is expected to reach a profit inflection point in 2026.
The report believes that the current price adjustment provides investors with a good opportunity to position themselves, and the next key observation point is the market response to new car models (such as ONVO L80) during the Beijing Auto Show in April 2026. Based on the above judgment, J.P. Morgan assigned a "neutral" rating to NIO Inc. Sponsored ADR Class A. In addition, NIO Inc. Sponsored ADR Class A announced its third quarter financial report for 2025 yesterday, showing that its delivery volume, revenue capability, and overall gross profit margin have all reached historical highs. The fourth quarter revenue guidance is between 32.76 billion yuan and 34.04 billion yuan, an increase of 66.3% to 72.8% year-on-year, setting new records and leading among new energy vehicle companies.
Related Articles

A-share evening hot spots | Six departments issue heavyweight documents related to promoting consumption

New Stock News | Baoji Pharmaceutical has passed the hearing of the Hong Kong Stock Exchange, and its core product SJ02 has obtained NDA approval from the National Medical Products Administration.

DOWWAY (08403) received an acquisition of controlling stake by Sun Wei and a discount of about 65.75% in cash tender offer. It will resume trading on November 27th.
A-share evening hot spots | Six departments issue heavyweight documents related to promoting consumption

New Stock News | Baoji Pharmaceutical has passed the hearing of the Hong Kong Stock Exchange, and its core product SJ02 has obtained NDA approval from the National Medical Products Administration.

DOWWAY (08403) received an acquisition of controlling stake by Sun Wei and a discount of about 65.75% in cash tender offer. It will resume trading on November 27th.

RECOMMEND

Foreign Brands “Take On Chinese Names”: Starbucks And Burger King Change Hands As Chinese Capital’s Localization Scalpel Rewrites Global Rules
25/11/2025

Riding The Momentum Of Gemini 3, “Google Chain” Challenges “Nvidia Chain,” Reshaping The Ai Trading Landscape
25/11/2025

Silver Economy Accelerates As Personal Pension System Marks Three Years — Structural Changes Emerging
25/11/2025


